Table 2 Response assessment criteria
RECIST | CHOI | mCHOI | MASS | |
|---|---|---|---|---|
Progressive disease (MASS unfavourable response) | Increase in sum of longest target lesion diameters >20%. or Development of new lesions. or Unequivocal non-target lesion progression. | Increase in lesion sizea > 10%. or Development of new lesions. or New or enlarging intratumoral nodule. | Increase in lesion sizea > 10%. or Development of new lesions. or New or enlarging intratumoral nodule. | Increase in lesion sizea > 20% without central necrosis. or Development of new lesions. or New intratumoral enhancing components. |
Partial response (MASS favourable response) | >30% decrease in sum of longest target lesion diameters. | Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10% | Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10% | Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units |
Complete response | Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm). | Disappearance of all target lesions | Disappearance of all target lesions | Disappearance of all target lesions |
Stable disease (MASS indeterminate response) | None of the above | None of the above | None of the above | None of the above |